Validation of Artificial Intelligence Enabled TB Screening and Diagnosis in Zambia
NCT ID: NCT05139940
Last Updated: 2025-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2432 participants
OBSERVATIONAL
2021-11-22
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Achieving Tuberculosis (TB) Control In Zambia
NCT03497195
Alternative Diagnoses in Patients About to Start Empiric Tuberculosis Treatment
NCT06737029
Evaluation of PTB Screening in ANC in Lusaka, Zambia
NCT02053129
AI-based System for Lung Tuberculosis Screening: Diagnostic Accuracy Evaluation
NCT05889364
Determining Risk in Latent Tuberculosis
NCT01571739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pilot Group to calibrate the operating points for AI algorithms (Estimated Enrollment up to 500)
Diagnostic Test: TB AI algorithm performance in detecting active TB.
Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)
Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.
Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.
Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count.
No interventions assigned to this group
Main Cross Sectional Group (Estimated Enrollment 1932 minus the volume in pilot)
Diagnostic Test: TB AI algorithm performance in detecting active TB.
Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)
Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.
Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.
Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presumptive TB patients defined as having any of the following:
○ Cough, Weight loss, Night sweats, Fever
* Household /close TB contacts regardless of symptoms
* Newly diagnosed HIV regardless of symptoms.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre for Infectious Disease Research in Zambia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chainda South Health Facility
Lusaka, Lusaka Province, Zambia
Chawama first level hospital
Lusaka, Lusaka Province, Zambia
Kanyama level 1
Lusaka, Lusaka Province, Zambia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Google AI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.